<DOC>
	<DOCNO>NCT00054587</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Radiation therapy use high-energy x-rays damage tumor cell . It yet know regimen chemotherapy plus radiation therapy without trastuzumab effective treat breast cancer . PURPOSE : Randomized phase III trial compare two different chemotherapy regimen plus radiation therapy without trastuzumab treat woman breast cancer spread lymph node axilla ( arm ) .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Trastuzumab Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy adjuvant cyclophosphamide , epirubicin , fluorouracil v adjuvant docetaxel epirubicin , term 5-year survival without relapse , woman nonmetastatic adenocarcinoma breast lymph node invasion . - Determine survival patient treat regimen . - Compare tolerability trastuzumab ( Herceptin ) patient treat regimen . - Determine efficacy tolerability trastuzumab patient hormone receptor-positive tumor . - Evaluate quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center . Patients treat 2 part . - Part I : Patients randomize 1 2 treatment arm . - Arm I : Patients receive fluorouracil IV , epirubicin IV , cyclophosphamide IV day 1 . Treatment repeat every 3 week 6 course . Patients undergo radiotherapy 5 day week 5 week . - Arm II : Patients receive epirubicin IV 10 minute docetaxel IV 1 hour day 1 . Treatment repeat every 3 week 6 course . Patients undergo radiotherapy arm I . Patients HER2/neu-positive tumor proceed part II . Patients HER2/neu-negative tumor receive treatment . Patients hormone ( estrogen progesterone ) receptor-positive tumor also receive oral tamoxifen daily begin chemotherapy complete continue 5 year . - Part II : Patients randomize 1 2 treatment arm . - Arm I : Patients receive trastuzumab ( Herceptin ) IV 30-90 minute every 3 week 1 year . - Arm II : Patients follow without treatment . Patients receive trastuzumab follow 4 month , 6 month , every 4 month 1 year , every 6 month 3 year . Patients receive trastuzumab follow 4 month every 6 month 3 year . PROJECTED ACCRUAL : A total 2,600 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonmetastatic , unilateral adenocarcinoma breast Axillary lymph node invasion ( N1 , N2 , N3 ) No cutaneous invasion No T4a great disease No clinically radiologically suspect metastases No clinically radiologically suspected contralateral lesion No deeply adherent inflammatory disease Complete surgical resection perform , include removal least 5 lymph node , residual tumor , within past 42 day No prior breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 64 Sex Female Menopausal status Not specify Performance status WHO 01 Life expectancy Not specify Hematopoietic WBC least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic ALT AST great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Bilirubin great ULN Hepatitis B hepatitis C negative No hepatic dysfunction Renal Creatinine le 1.3 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular ECHO normal LVEF least 50 % Pulmonary FEV normal No dyspnea rest No supplemental oxygen dependence Other Not pregnant Fertile patient must use effective contraception HIV negative No active infection No prior malignancy except basal cell skin cancer carcinoma situ cervix No contraindication anthracycline therapy No chronic medical psychological condition No geographic social reason would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy No concurrent chemotherapy No contraindication anthracycline therapy Endocrine therapy No prior hormonal therapy Radiotherapy No prior radiotherapy Surgery See Disease Characteristics Other At least 4 week since prior experimental therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>